

Caldesmon Regulates Axon Extension through Interaction with Myosin II*

Received for publication, August 18, 2011, and in revised form, November 27, 2011. Published, JBC Papers in Press, December 9, 2011, DOI 10.1074/jbc.M111.295618

Tsuyoshi Morita[‡], Taira Mayanagi^{‡§}, and Kenji Sobue^{‡§1}

From the [‡]Department of Neuroscience, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan and the [§]Department of Neuroscience, Institute for Biomedical Sciences, Iwate Medical University, 2-1-1 Nishitokuta, Yahaba-cho, Shiwa-gun, Iwate 028-3694, Japan

Background: Axon extension, an essential step for creating neural circuits, is regulated by cytoskeletal dynamics.

Results: Caldesmon is a regulator of the actin cytoskeleton and enhances axon extension through direct interaction with myosin II.

Conclusion: Caldesmon binding to myosin II inhibits myosin II function, resulting in the enhancement of axon extension.

Significance: This study elucidates how caldesmon-regulated actin-myosin system is involved in axon extension.

To begin the process of forming neural circuits, new neurons first establish their polarity and extend their axon. Axon extension is guided and regulated by highly coordinated cytoskeletal dynamics. Here we demonstrate that in hippocampal neurons, the actin-binding protein caldesmon accumulates in distal axons, and its N-terminal interaction with myosin II enhances axon extension. In cortical neural progenitor cells, caldesmon knockdown suppresses axon extension and neuronal polarity. These results indicate that caldesmon is an important regulator of axon development.

Neurons in the developing brain extend axonal and dendritic arbors that create a complex circuitry, and the guided extension of axonal fibers is an essential step in this process. Axon extension is regulated by the coordinated interaction of microtubules and actin filaments in the axonal growth cone. A growing body of evidence indicates that microtubule polymerization and stabilization play positive roles in axon extension (1), whereas actin filament roles are more complicated. For example, knocking out Ena/VASP or Cdc42, which positively regulate actin polymerization, causes axonal tract loss (2, 3). In contrast, inhibiting the actin nucleation factor Arp2/3 and pharmacologically destabilizing actin filaments enhances axon extension (4, 5). Thus, the fundamental details of axon guidance and regulation by actin filaments are not well understood.

Caldesmon (CaD)² was first identified as a smooth-muscle protein that binds calmodulin and actin (6). It has since been found to be ubiquitously expressed in smooth muscle and non-muscle cells, and to regulate Ca²⁺-dependent actomyosin contraction (7, 8). CaD binds to the side of filamentous actin (F-actin) and inhibits actin-myosin interactions, as revealed by

superprecipitation assays and actin-activated myosin ATPase activity (9–11). CaD binding also stabilizes F-actin filaments by enhancing actin-tropomyosin binding and preventing the actin-severing activity of gelsolin or cofilin (12, 13). CaD plays important roles in migration of non-muscle cells via regulating actin-myosin system (8). We recently reported that CaD is involved in detrimental glucocorticoid-induced effects during cortical brain development (14, 15): glucocorticoids increase CaD levels, transiently retarding the radial migration of cortical neuronal progenitor cells. We also reported that CaD localizes to neuronal growth cones (16). Thus, it seems that CaD plays multiple important roles in neuronal development. In this report, we demonstrate a novel role for CaD in axon extension via its N-terminal myosin binding sequence.

EXPERIMENTAL PROCEDURES

Materials—The myosin II ATPase inhibitor blebbistatin, the myosin light chain kinase inhibitor ML-7, and the Rho-associated protein kinase inhibitor Y27632 were purchased from Merck. The following antibodies were purchased: anti-tau1 (Chemicon), anti-MAP2 (Chemicon), anti-nonmuscle myosin IIA (Abcam), anti-nonmuscle myosin IIB (Abcam), anti-GFP (Invitrogen), anti-FLAG (Sigma), anti-Myc (9E10, Santa Cruz Biotechnology), and anti-GAPDH (FL-335, Santa Cruz Biotechnology). Anti-CaD antibody was generated as previously described (17).

Cell Culture and Immunostaining—Hippocampal neurons were prepared from rat hippocampi on embryonic day 18.5. The dissociated neurons were plated on poly-L-lysine-coated coverslips, and cultured in glial-conditioned MEM containing 1 mM pyruvate, 0.6% (w/v) D-glucose, and 2% B27 supplement (Invitrogen). The next day, the culture was changed to a neurobasal medium containing 2% B27 supplement and 0.5 mM L-glutamine. Cortical NPCs were prepared from rat cerebral cortex on embryonic day 15.5 (E15.5), cultured as previously described (14), plated on laminin-coated coverslips, and cultured under basic FGF-free conditions to induce their differentiation into polarized neurons. A549 and HEK293T cells were cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum. Cells cultured on coverslips were fixed using 4% paraformaldehyde and then processed for immunocyto-

* This work was supported by Grants-in-aid for Scientific Research 20240038 from the Japan Society for the Promotion of Science (to K. S.) and 23110510 from the Ministry of Education, Culture, Sports, Science and Technology (MEXT) (to K. S.).

¹ To whom correspondence should be addressed: Dept. of Neuroscience, Institute for Biomedical Sciences, Iwate Medical University, 2-1-1 Nishitokuta, Yahaba-cho, Shiwa-gun, Iwate 028-3694, Japan. Tel.: 81-19-651-5710; Fax: 81-19-908-8020; E-mail: ksobue@iwate-med.ac.jp.

² The abbreviations used are: CaD, caldesmon; DIV, day *in vitro*; NPCs, neural progenitor cells; FGF, fibroblast growth factor; HMM, heavy meromyosin.

Caldesmon Regulates Axon Extension




FIGURE 1. CaD involvement in axon extension. *A*, CaD protein localization in primary cultured hippocampal neurons. The neurons were fixed and triple-stained with anti-CaD, anti-tau1 antibodies, and phalloidin (F-actin). Bar, 50 μm . *B*, dendrite and axon fluorescence intensities measured in the CaD-immunostained image shown in *A*; arrows indicate growth cones. *C*, neurons, which had been transfected with GFP as a cell volume maker, were fixed and triple-stained with anti-CaD, anti-GFP, and anti-tau1 antibodies. Bar, 50 μm . *D*, dendrite and axon fluorescence intensities were measured in the CaD-immunostained and GFP-immunostained images shown in *C*, respectively, and then GFP-intensity was subtracted from CaD-intensity to correct for the influence of cell volume. Arrows indicate growth cones. *E*, changes in CaD protein expression during neuronal development. *F*, morphology of GFP- or GFP-CaD-transfected neurons after 3 days in culture (bar, 100 μm) and *G*, quantification of their axonal and dendritic length. Axonal length represents the longest axon branch. Data are means \pm S.E. from six independent experiments. *H*, morphology of CaD-induced filopodia-like protrusions. The myc-CaD-transfected neurons were fixed and stained with anti-tubulin and phalloidin (F-actin). Bar, 25 μm . *I*, morphology of neurons transfected with control miRNA, CaD miRNA1, or CaD miRNA2, and cultured for 5 days (bar, 100 μm), and *J*, quantification their axonal and dendritic lengths. Data are means \pm S.E. from four to six independent experiments.

chemistry. To label F-actin, Alexa 568-phalloidin (Molecular Probes) was added to the secondary antibody solution.

Transfection—Hippocampal neurons prepared from rat embryos on E18.5 were transfected by the calcium phosphate method as described previously (18). In brief, DNA-calcium phosphate precipitates were prepared using a calcium phosphate transfection kit (Invitrogen). The hippocampal neurons were plated on a Nunclon Δ surface plate (Nalge Nunc Interna-

tional) and incubated with the precipitates for 3 h. The transfected neurons were replated on poly-L-lysine-coated coverslips and cultured for 3 to 5 days. A549 and HEK293T cells were transfected using Lipofectamine 2000 or Lipofectamine LTX (Invitrogen).

Expression Plasmids—The coding regions for human l-CaD, its N terminus (1–263 amino acids), C terminus (264–558 amino acids), and N terminus Δ 21–47 (lacking amino acids




FIGURE 2. CaD involvement in cortical NPC axon development. *A*, proliferating cortical NPCs were incubated with control siRNA, CaD siRNA1, or CaD siRNA2 for 3 days, and cultured in basic FGF-free medium for 3 days. The cultured cells were fixed and stained with anti-tau1 (green) and anti-MAP2 (red) antibodies. Bar, 200 μ m. *B*, percentage of tau1-negative non-polarized cells among the differentiating progenitor cells. Data are means \pm S.E. from at least 120 cells. *C*, quantification of axonal length in tau1-positive cells. Data are means \pm S.E. from at least 30 cells.

21–47 from the N terminus), and the N-terminal fragments of rat myosin IIA (1–1961 amino acids) and IIB (1–1976 amino acids) were amplified by PCR and subcloned into the highly efficient mammalian expression plasmid pCAGGS. EGFP and Myc tag sequences were fused to the 5'-end of the coding sequences. The mcherry-LifeAct expression vector was constructed as previously reported (19).

RNA Interference—Short-interfering RNAs (siRNAs) against rat CaD were transfected into growing cortical NPCs using Lipofectamine RNAi MAX (Invitrogen). MicroRNA (miRNA) plasmids against rat CaD were constructed as previously described (14) and transfected into hippocampal neurons by calcium phosphate precipitation. The targeting sequences and the siRNA and miRNA knockdown efficacy were reported in our previous studies (14, 20).

Immunoprecipitation—HEK293T cells with transfected expression vectors were lysed with Triton-X-buffer (0.05% Triton X-100 (pH 7.6), 30 mM Tris-HCl, 50 mM NaCl 5 mM EGTA, 5 mM MgCl₂, 1 mM ATP, and protease inhibitor mixture for use with mammalian cell and tissue extracts (Nacalai Tesque)). Immunoprecipitation was performed using the earlier-listed antibodies and protein G-Sepharose (GE Healthcare Life Sciences). The Sepharose beads were boiled in SDS-sample buffer to elute the immunocomplexes.

RESULTS

CaD Enhances Axon Extension in Hippocampal Neurons—CaD, a ubiquitous regulator of the actin cytoskeleton, localizes along actin fibers and in the ruffling membrane (7, 8). Here, we found that CaD was located in the soma and growth cones of primary cultured hippocampal neurons, with the strongest expression in the distal axon (Fig. 1, *A–D*). CaD levels increased for 3 to 7 days *in vitro* (DIV) (2.3 ± 0.8 -fold at 7 DIV *versus* 2 DIV) while the neurons established polarity and actively extended axons (Fig. 1*E*). The location and time-course of CaD expression in these cells are consistent with its having a role in axon extension.

We therefore investigated CaD function in neurite outgrowth by overexpressing or knocking down CaD in hippocampal neurons. We used GFP-fused CaD (GFP-CaD), which has the same functions as endogenous CaD (14, 20). GFP-CaD dramatically enhanced axon extension but did not significantly affect dendrite length as compared with the control, GFP (Fig. 1, *F* and *G*). GFP-CaD also enhanced formation of filopodia-like

protrusions from the soma and axon branches (Fig. 1*F*). These CaD-induced protrusions were composed of concentrated actin filaments and were distinct from the main axonal branches, which were filled with microtubules (Fig. 1*H*). Knocking down the endogenous CaD decreased axon length, but not dendritic length (Fig. 1, *I* and *J*), indicating that CaD accumulates in the distal axon of hippocampal neurons during their development and enhances axon extension.

CaD Regulates Axon Development in Cortical NPCs—To monitor CaD involvement in early events in neurite outgrowth, we used cortical neural progenitor cells (NPCs), which proliferate as non-polarized cells in the presence of basic fibroblast growth factor (FGF) (14, 21). Under basic FGF-free conditions, however, NPCs stop proliferating and establish neuronal polarity with MAP2-positive dendrites and a tau1-positive axon (Fig. 2*A*). When CaD was knocked down with siRNAs in proliferating NPCs, tau1-staining showed that the establishment of neuronal polarity was significantly suppressed within three culture days under basic FGF-free conditions (Fig. 2, *A* and *B*). Even in polarized cells, the length of tau1-positive axons was significantly shortened by CaD knockdown (Fig. 2, *A* and *C*), as observed in hippocampal neurons. At an early stage of NPCs differentiation into polarized cells, immature axons were often stained with both anti-MAP2 and anti-tau1 antibodies. In the CaD-knockdown NPCs, some short axons were MAP2/tau1 double positive, suggesting delayed development of these cells. These findings indicate that CaD plays important roles in establishing neuronal polarity and in axon extension in developing NPCs.

CaD-Myosin Interaction Required for Axon Extension—CaD has been reported to bind smooth muscle myosin at its N terminus and F-actin at its C terminus, suggesting that it functions to link these molecules (22). In the growth cone of hippocampal neuronal axons, CaD colocalized with F-actin and myosin IIA/IIB, the major non-muscle isoforms of myosin II (Fig. 3*A*). To examine myosin and actin involvement in CaD-induced axon extension, CaD N- and C-terminal fragments (N-CaD and C-CaD) were expressed separately in hippocampal neurons. N-CaD enhanced axon extension like full-length CaD, but C-CaD did not (Fig. 3, *B–D*), suggesting that CaD interaction with myosin, but not F-actin, is necessary for CaD-induced axon extension. On the other hand, C-CaD, but not N-CaD, induced formation of the filopodia-like protrusions like full-

Caldesmon Regulates Axon Extension




FIGURE 3. The effect of CaD N- and C-terminal fragments on axon extension. *A*, CaD, myosin IIA, and myosin IIB localization in the hippocampal neuron axonal growth cone. Bar, 10 μm . *B*, CaD domain structure. *C*, morphology of neurons cultured for 3 days after transfection with GFP, GFP-N-CaD, GFP-C-CaD, or GFP-N-CaD Δ 21–47 (bar, 100 μm), and *D*, quantification of their axonal length. Data are means \pm S.E. of values from four to six independent experiments. *E*, quantification of their filipodial density. Data are means \pm S.E. of values from four to six independent experiments.




FIGURE 4. CaD and myosin II interactions. *A*, HEK 293T cells transfected with myc-CaD and FLAG-HMM IIA or FLAG-HMM IIB were immunoprecipitated using anti-Myc antibody or *B*, anti-FLAG antibody. *C*, HEK 293T cells were transfected with FLAG-HMM IIA and GFP, GFP-CaD, GFP-N-CaD, GFP-N-CaD Δ 21–47, or GFP-C-CaD and immunoprecipitated with anti-GFP antibody. *Arrowhead*: IgG light chain position. *D*, HEK 293T cells were transfected with FLAG-HMM IIA and GFP, GFP-CaD Δ 21–47, or GFP-CaD and immunoprecipitated with anti-GFP antibody. *Arrowhead*: IgG light chain position.

length CaD (Figs. 1*F* and 3, *C* and *E*), suggesting that this effect is dependent on the C-terminal actin binding domains.

Co-immunoprecipitation was used to determine whether non-muscle myosin II, like smooth- and skeletal-muscle myosins, binds to CaD. Because CaD is reported to bind to the S-1 and S-2 regions of smooth and skeletal muscle myosins (23), we examined CaD interactions with myosin IIA or IIB N-terminal fragments, which are composed of a globular head domain, a neck region, and a small tail fragment corresponding to heavy meromyosin (HMM). As with smooth and skeletal muscle myosins, CaD bound to HMM IIA and IIB, and CaD's C-termi-

nal F-actin-binding domains were not necessary for these interactions (Fig. 4, *A–C*).

Previous studies demonstrated that the 27-amino acid sequence in CaD's N terminus (Tyr-21 to Lys-47 in human I-CaD) is necessary for binding to smooth-muscle myosin (24). N-CaD Δ 21–47 fragment, in which this 27-amino acid sequence is deleted, did not interact with HMM IIA, and a CaD fragment including amino acids 1–47 was the minimum required for HMM IIA binding (Fig. 4, *C* and *D*). Importantly, N-CaD Δ 21–47 fragment completely lost the ability to enhance axon extension (Fig. 3, *C* and *D*), strongly supporting the idea that CaD is accumulated in the growth cone as




FIGURE 5. CaD fragments ectopically expressed in A549 cells. A549 cells transfected with GFP, GFP-C-CaD, GFP-N-CaD, or GFP-N-CaD Δ 21–47 were fixed and stained with anti-GFP antibody (green) and phalloidin (F-actin, red). At right, cells were treated with 10 μ M blebbistatin (blebb) for 30 min and then fixed and stained with phalloidin. Bar, 100 μ m. *B*, quantification of fluorescence intensity of phalloidin staining in GFP-positive and GFP-negative cells, respectively.

an actomyosin component and enhances axon extension through direct interaction with non-muscle myosin II.

N-CaD Exhibits the Same Effect as Blebbistatin—To determine the significance of CaD interaction with myosin, N-CaD or C-CaD was transfected into A549 cells. CaD has been reported to stabilize actin filaments via its C-terminal F-actin-binding domains, causing thick actin fibers to form (12, 26). In A549 cells, C-CaD strongly induced thick actin fiber formation (Fig. 5, *A* and *B*). On the other hand, cells expressing N-CaD showed significant actin fiber loss and a flat cell shape with prominent lamellipodia (Fig. 5, *A* and *B*). These effects were completely lost in A549 cells expressing an N-CaD Δ 21–47 fragment lacking the 27-amino acid myosin-binding sequence (Fig. 5, *A* and *B*). Further, these morphological changes were very similar to those found in cells treated with the myosin II-inhibitor blebbistatin (Fig. 5*A*). These results suggest that CaD binds to myosin at its N terminus, and that it inhibits myosin II function independently of its C-terminal F-actin-binding domains.

CaD Changes Growth Cone Morphology and Myosin II Localization—To determine the function of CaD in growth cones, we observed growth cone morphology and myosin II localization in the hippocampal neurons expressing CaD fragments (Fig. 6). N-CaD inhibited lamellipodia expansion, whereas C-CaD enhanced filopodia formation in growth cones. Full-length CaD induced both lamellipodia retraction and filopodia formation. N-CaD Δ 21–47 had no effect on growth cone morphology.




FIGURE 6. The effect of CaD fragments on growth cone morphology and myosin II localization. Hippocampal neurons transfected with GFP, GFP-C-CaD, GFP-N-CaD, GFP-N-CaD Δ 21–47, or GFP-CaD were fixed and stained with anti-GFP (green) and anti-myosin IIA or IIB (red) antibodies. Bar, 10 μ m.




FIGURE 7. Myosin II functions in CaD-enhanced axon extension. *A*, hippocampal neurons were cultured with 10 μM blebbistatin, 50 μM ML-7, or 10 μM Y27632 for 3 days, and then fixed and stained with anti-tau1 (green) and anti-MAP2 (red) antibodies (bar, 400 μm); *B*, quantification of axonal length in these neurons. Data are means \pm S.E. of values from at least 70 cells. *C*, primary cultured hippocampal neurons transfected with GFP or GFP-CaD and incubated with or without 10 μM blebbistatin for 3 days (bar, 100 μm); *D*, quantification of axonal length in these neurons. Data are means \pm S.E. from four independent experiments. *E*, growth cone morphology in GFP- or GFP-CaD-transfected neurons before or after treatment with 10 μM blebbistatin for 30 min. To visualize F-actin in living neurons, the cells were transfected with mcherry-LifeAct. Bar, 20 μm .

In GFP-N-CaD-transfected neurons, myosin II staining was slightly diffuse, but distinctly strong in the basal region of the lamellipodia-poor growth cones. In the cells transfected with GFP-CaD and GFP-C-CaD, myosin II was tightly associated with filopodia. N-CaD $\Delta 21-47$ had no effect on myosin II localization. These results indicate that C-terminal actin binding domains enhances actin bundling in growth cones, leading to filopodia formation, with which myosin II associates. On the other hand, N-terminal myosin-binding domain inhibits lamellipodia formation in growth cone, but scarcely have an effect on the myosin II localization.

CaD Enhances Axon Extension by Inhibiting Myosin—To examine how inhibiting myosin function would affect axon extension, hippocampal neurons were incubated with blebbistatin, myosin light chain kinase inhibitor ML-7, or Rho-associated protein kinase inhibitor Y27632, drugs that directly or indirectly inhibit myosin function. All of these drugs, especially the direct inhibitor blebbistatin, significantly increased axonal length compared with the vehicle control (Fig. 7, *A* and *B*). In GFP-CaD-transfected hippocampal neurons, however, blebbistatin did not further accelerate axon extension (Fig. 7, *C* and *D*). Coupled with its effects on axon extension, blebbistatin induced morphological changes in the axonal growth cones, inducing a switch from lamellipodial to filopodia-like protrusions (Fig. 7*E*). In the GFP-CaD-transfected neurons, axonal growth cones displayed a filopodia-like morphology without

expanded lamellipodia, and their morphology was not affected by blebbistatin treatment (Fig. 7*E*). These findings indicate that blebbistatin and CaD enhance axon extension via the same pathway, through which myosin II function is inhibited.

DISCUSSION

CaD is a ubiquitous regulator of the actin cytoskeleton. Most of CaD functional domains that bind F-actin, tropomyosin, and calmodulin are located in its C terminus, and the C-terminal fragment can inhibit myosin ATPase activity and stabilize actin filaments (8, 12, 26–28). CaD N-terminal region also has a myosin-binding sequence, through which CaD binds to smooth and skeletal muscle heavy meromyosins (23). This binding domain is probably involved in tethering myosin to actin filaments (22, 29), but the significance of myosin binding to CaD had been unclear. In our present study, we clearly demonstrated that CaD enhances axon extension through direct interaction with non-muscle myosin II via its N-terminal myosin-binding sequence. N-CaD, which lacks the all C-terminal functional domains, exhibited the same effect on axon extension as full-length CaD (Fig. 3, *C* and *D*), indicating that axon extension does not depend on the CaD-mediated physical bridge between myosin and actin.

In addition to axon extension, CaD induced formation of the filopodia-like protrusions from soma and axon branches (Figs. 1*F* and 3*E*). CaD also enhanced filopodia formation in growth

cones (Fig. 6). C terminus of CaD, but not N terminus, was required for both functions. C terminus contains some actin binding domains, which are necessary for stabilization of actin bundles (7, 8), and the filopodia-like protrusion were composed of concentrated actin filaments (Fig. 1H). These indicate that actin stabilization by the C-terminal domains facilitates formation of these filopodial protrusions independently of N-terminal myosin binding domain.

Results of our experiments using myosin II ATPase inhibitor blebbistatin strongly suggest an inhibitory effect of N-CaD on myosin II function in hippocampal neurons and non-neuronal A549 cells (Figs. 5 and 7). However, previous *in vitro* study showed that the CaD¹⁻⁵⁹⁷ fragment, which lacks the C-terminal actin-binding domains, does not inhibit actin-activated myosin ATPase activity (29). Velaz *et al.* (22) reported that CaD inhibits actin-activated myosin ATPase activity via its C-terminal F-actin-binding domains, by preventing the myosin head from binding to actin *in vitro* (21). Considering the discrepancy between these *in vitro* studies and our *in vivo* study, we propose that N-CaD inhibits myosin II function by unknown mechanisms, which may include interacting with or recruiting additional myosin-inhibitory factors. Further investigations are required to clarify how N-CaD inhibits myosin II function.

Growing evidences indicate that myosin II function is important for axon outgrowth and axon guidance (30–35). However, the molecular mechanism underlying actomyosin-mediated axon extension has not been fully evaluated. An early study by Letourneau *et al.* (36) clearly demonstrated that both “push” by microtubules and “pull” by actomyosin in the growth cone play central roles in axon extension. Actually, actin destabilization by cytochalasin D or ADF/cofilin and myosin II inhibition by blebbistatin enhance axon extension (Refs. 5, 25 and the present study). CaD may inhibit the traction force generated by the actomyosin contraction, thereby augmenting the pushing force from microtubule extension.

REFERENCES

- Poulain, F. E., and Sobel, A. (2010) The microtubule network and neuronal morphogenesis: Dynamic and coordinated orchestration through multiple players. *Mol. Cell. Neurosci.* **43**, 15–32
- Kwiatkowski, A. V., Rubinson, D. A., Dent, E. W., Edward van Veen, J., Leslie, J. D., Zhang, J., Mebane, L. M., Philippart, U., Pinheiro, E. M., Burds, A. A., Bronson, R. T., Mori, S., Fässler, R., and Gertler, F. B. (2007) Ena/VASP Is required for neurogenesis in the developing cortex. *Neuron* **56**, 441–455
- Garvalov, B. K., Flynn, K. C., Neukirchen, D., Meyn, L., Teusch, N., Wu, X., Brakebusch, C., Bamberg, J. R., and Bradke, F. (2007) Cdc42 regulates cofilin during the establishment of neuronal polarity. *J. Neurosci.* **27**, 13117–13129
- Strasser, G. A., Rahim, N. A., VanderWaal, K. E., Gertler, F. B., and Lanier, L. M. (2004) Arp2/3 is a negative regulator of growth cone translocation. *Neuron* **43**, 81–94
- Bradke, F., and Dotti, C. G. (1999) The role of local actin instability in axon formation. *Science* **283**, 1931–1934
- Sobue, K., Muramoto, Y., Fujita, M., and Kakiuchi, S. (1981) Purification of a calmodulin-binding protein from chicken gizzard that interacts with F-actin. *Proc. Natl. Acad. Sci. U.S.A.* **78**, 5652–5655
- Sobue, K., and Sellers, J. R. (1991) Caldesmon, a novel regulatory protein in smooth muscle and nonmuscle actomyosin systems. *J. Biol. Chem.* **266**, 12115–12118
- Mayanagi, T., and Sobue, K. (2011) Diversification of caldesmon-linked actin cytoskeleton in cell motility. *Cell. Adh. Migr.* **5**, 150–159
- Sobue, K., Morimoto, K., Inui, M., Kanda, K., and Kakiuchi, S. (1982) *Biomed. Res.* **3**, 188–196
- Ngai, P. K., and Walsh, M. P. (1984) Inhibition of smooth muscle actin-activated myosin Mg²⁺-ATPase activity by caldesmon. *J. Biol. Chem.* **259**, 13656–13659
- Sobue, K., Takahashi, K., and Wakabayashi, I. (1985) Caldesmon150 regulates the tropomyosin-enhanced actin-myosin interaction in gizzard smooth muscle. *Biochem. Biophys. Res. Commun.* **132**, 645–651
- Ishikawa, R., Yamashiro, S., and Matsumura, F. (1989) Differential modulation of actin-severing activity of gelsolin by multiple isoforms of cultured rat cell tropomyosin. Potentiation of protective ability of tropomyosins by 83-kDa nonmuscle caldesmon. *J. Biol. Chem.* **264**, 7490–7497
- Yamashiro, S., Chern, H., Yamakita, Y., and Matsumura, F. (2001) Mutant Caldesmon lacking cdc2 phosphorylation sites delays M-phase entry and inhibits cytokinesis. *Mol. Biol. Cell* **12**, 239–250
- Fukumoto, K., Morita, T., Mayanagi, T., Tanokashira, D., Yoshida, T., Sakai, A., and Sobue, K. (2009) Detrimental effects of glucocorticoids on neuronal migration during brain development. *Mol. Psychiatry* **14**, 1119–1131
- Sobue, K., and Fukumoto, K. (2010) Caldesmon, an actin-linked regulatory protein, comes across glucocorticoids. *Cell Adh. Migr.* **4**, 185–189
- Kira, M., Tanaka, J., and Sobue, K. (1995) Caldesmon and low Mr isoform of tropomyosin are localized in neuronal growth cones. *J. Neurosci. Res.* **40**, 294–305
- Tanaka, J., Watanabe, T., Nakamura, N., and Sobue, K. (1993) Morphological and biochemical analyses of contractile proteins (actin, myosin, caldesmon and tropomyosin) in normal and transformed cells. *J. Cell Sci.* **104**, 595–606
- Jiang, M., and Chen, G. (2006) High Ca²⁺-phosphate transfection efficiency in low-density neuronal cultures. *Nat. Protoc.* **1**, 695–700
- Riedl, J., Crevenna, A. H., Kessenbrock, K., Yu, J. H., Neukirchen, D., Bista, M., Bradke, F., Jenne, D., Holak, T. A., Werb, Z., Sixt, M., and Wedlich-Soldner, R. (2008) Lifeact: a versatile marker to visualize F-actin. *Nat. Methods* **5**, 605–607
- Morita, T., Mayanagi, T., Yoshio, T., and Sobue, K. (2007) Changes in the balance between caldesmon regulated by p21-activated kinases and the Arp2/3 complex govern podosome formation. *J. Biol. Chem.* **282**, 8454–8463
- Ray, J., Peterson, D. A., Schinstine, M., and Gage, F. H. (1993) Proliferation, differentiation, and long-term culture of primary hippocampal neurons. *Proc. Natl. Acad. Sci. U.S.A.* **90**, 3602–3606
- Velaz, L., Ingraham, R. H., and Chalovich, J. M. (1990) Dissociation of the effect of caldesmon on the ATPase activity and on the binding of smooth heavy meromyosin to actin by partial digestion of caldesmon. *J. Biol. Chem.* **265**, 2929–2934
- Hemric, M. E., and Chalovich, J. M. (1988) Effect of caldesmon on the ATPase activity and the binding of smooth and skeletal myosin subfragments to actin. *J. Biol. Chem.* **263**, 1878–1885
- Li, Y., Zhuang, S., Guo, H., Mabuchi, K., Lu, R. C., and Wang, C. A. (2000) The major myosin-binding site of caldesmon resides near its N-terminal extreme. *J. Biol. Chem.* **275**, 10989–10994
- Kuhn, T. B., Meberg, P. J., Brown, M. D., Bernstein, B. W., Minamide, L. S., Jensen, J. R., Okada, K., Soda, E. A., and Bamberg, J. R. (2000) Regulating actin dynamics in neuronal growth cones by ADF/cofilin and rho family GTPases. *J. Neurobiol.* **44**, 126–144
- Warren, K. S., Lin, J. L., Wamblodt, D. D., and Lin, J. J. (1994) Overexpression of human fibroblast caldesmon fragment containing actin-, Ca⁺⁺/calmodulin-, and tropomyosin-binding domains stabilizes endogenous tropomyosin and microfilaments. *J. Cell Biol.* **125**, 359–368
- Hayashi, K., Fujio, Y., Kato, I., and Sobue, K. (1991) Structural and functional relationships between h- and l-caldesmons. *J. Biol. Chem.* **266**, 355–361
- Li, Y., Lin, J. L., Reiter, R. S., Daniels, K., Soll, D. R., and Lin, J. J. (2004) Caldesmon mutant defective in Ca(2+)-calmodulin binding interferes with assembly of stress fibers and affects cell morphology, growth, and motility. *J. Cell Sci.* **117**, 3593–3604
- Wang, Z., Jiang, H., Yang, Z. Q., and Chacko, S. (1997) Both N-terminal myosin-binding and C-terminal actin-binding sites on smooth muscle

Caldesmon Regulates Axon Extension

- caldesmon are required for caldesmon-mediated inhibition of actin filament velocity. *Proc. Natl. Acad. Sci. U.S.A.* **94**, 11899–11904
30. Chantler, P. D., and Wylie, S. R. (2003) Elucidation of the separate roles of myosins IIA and IIB during neurite outgrowth, adhesion and retraction. *IEE Proc. Nanobiotechnol.* **150**, 111–125
 31. Turney, S. G., and Bridgman, P. C. (2005) Laminin stimulates and guides axonal outgrowth via growth cone myosin II activity. *Nat. Neurosci.* **8**, 717–719
 32. Loudon, R. P., Silver, L. D., Yee, H. F., Jr., and Gallo, G. (2006) RhoA-kinase and myosin II are required for the maintenance of growth cone polarity and guidance by nerve growth factor. *J. Neurobiol.* **66**, 847–867
 33. Rösner, H., Möller, W., Wassermann, T., Mihatsch, J., and Blum, M. (2007) Attenuation of actinomyosinII contractile activity in growth cones accelerates filopodia-guided and microtubule-based neurite elongation. *Brain Res.* **1176**, 1–10
 34. Bridgman, P. C. (2009) Myosin motor proteins in the cell biology of axons and other neuronal compartments. *Results Probl. Cell Differ.* **48**, 91–105
 35. Hur, E. M., Yang, I. H., Kim, D. H., Byun, J., Saijilafu, Xu, W. L., Nicovich, P. R., Cheong, R., Levchenko, A., Thakor, N., and Zhou, F. Q. (2011) Engineering neuronal growth cones to promote axon regeneration over inhibitory molecules. *Proc. Natl. Acad. Sci. U.S.A.* **108**, 5057–5062
 36. Letourneau, P. C., Shattuck, T. A., and Ressler, A. H. (1987) “Pull” and “push” in neurite elongation: observations on the effects of different concentrations of cytochalasin B and taxol. *Cell Motil. Cytoskeleton* **8**, 193–209